MedTrace Logo

Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography

NCT03266562 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2019-05-09

No results posted yet for this study

Summary

The primary objective of this study is to determine the correlation between the distribution of F-18 FES within ER+ breast tumors as seen on Positron Emission Mammography (PEM) images of the breast, and the distribution of cells stained ER+ within the tumor by immunohistochemistry (IHC) measurements at surgical pathology. The secondary aim is to determine if the correlation (or lack of) between F-18 FES uptake and F-18 FDG uptake as imaged by PEM, is an accurate representation of the heterogeneity of ER expression in the tumor.

Conditions

  • Breast Neoplasm

Interventions

DIAGNOSTIC_TEST

F-18 FES

Evaluate uptake of F-18 FES in breast tissue

DIAGNOSTIC_TEST

F-18 FDG

Evaluate uptake of F-18 FDG in breast tissue

Sponsors & Collaborators

Principal Investigators

  • Michael K O'Connor, Ph.D · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2019-04-30
Completion
2019-04-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03266562 on ClinicalTrials.gov